On Invalid Date, Lineage Cell Therapeutics (NYSEMKT: LCTX) reported Q4 2023 earnings per share (EPS) of -$0.02, up 33.33% year over year. Total Lineage Cell Therapeutics earnings for the quarter were -$4.78 million. In the same quarter last year, Lineage Cell Therapeutics's earnings per share (EPS) was -$0.03.
As of Q1 2024, Lineage Cell Therapeutics's earnings has grown year over year. Lineage Cell Therapeutics's earnings in the past year totalled -$21.49 million.
What is LCTX's earnings date?
Lineage Cell Therapeutics's earnings date is Invalid Date. Add LCTX to your watchlist to be reminded of LCTX's next earnings announcement.
What was LCTX's revenue last quarter?
On Invalid Date, Lineage Cell Therapeutics (NYSEMKT: LCTX) reported Q4 2023 revenue of $2.09 million up 9.03% year over year. In the same quarter last year, Lineage Cell Therapeutics's revenue was $1.92 million.
What was LCTX's revenue growth in the past year?
As of Q1 2024, Lineage Cell Therapeutics's revenue has grown -39.16% year over year. This is 208.46 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Lineage Cell Therapeutics's revenue in the past year totalled $8.95 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.